The relationship between FOXD2-AS1 expression and the clinicopathological characteristics of glioma patients was further analyzed, and it was found that the expression level of FOXD2-AS1 was not associated with the gender, age and histological type of patients (all P > 0.05), but related to tumor diameter and WHO classification, lymph node metastasis and TMZ drug resistance (all P < 0.05) (Table 1). This evidence concerns the gene FOXD2 and central nervous system cancer.